-
13304-5A biotinylating reagent that contains two aminohexanoic spacers to increase the efficiency of avidin-binding by alleviating steric hindrance.
-
14242-1A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-10A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-25A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-5A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
11054-1A synthetic intermediate for pharmaceutical synthesis.
-
11054-5A synthetic intermediate for pharmaceutical synthesis.
-
11054-500A synthetic intermediate for pharmaceutical synthesis.
-
11986-10A selective, positive allosteric modulator of mGluR2, stimulating the human and rat receptors with EC50 values of 33.2 and 96 nM, respectively can be used on cells, tissues, or animals.
-
11986-25A selective, positive allosteric modulator of mGluR2, stimulating the human and rat receptors with EC50 values of 33.2 and 96 nM, respectively can be used on cells, tissues, or animals.
-
11986-5A selective, positive allosteric modulator of mGluR2, stimulating the human and rat receptors with EC50 values of 33.2 and 96 nM, respectively can be used on cells, tissues, or animals.
-
19699-1An antagonist of cIAP1, cIAP2, and XIAP.